Chromosomal analysis or the study of genetic differences in patients previously untreated with AML, ALL, MDS or MM may be helpful in the diagnosis and classification of disease. It may also improve the ability to predict the course of disease and the selection of therapy. Institutions must have either an Alliance-approved cytogeneticist or an agreement from an Alliance-approved main member cytogenetics laboratory to enroll a patient on CALGB 8461. The Alliance Approved Institutional Cytogeneticists list is posted on the Alliance for Clinical Trials in Oncology website.
Study Type
OBSERVATIONAL
Enrollment
9,000
Rebecca and John Moores UCSD Cancer Center
La Jolla, California, United States
Camino Medical Group - Treatment Center
Mountain View, California, United States
Kaiser Permanente Medical Office -Vandever Medical Office
San Diego, California, United States
Naval Medical Center - San Diego
San Diego, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Determine the incidence of specific less common primary as well as common secondary chromosome abnormalities in adult AML, ALL, MDS and MM
Time frame: Up to 10 years
Correlate specific (normal or various primary and secondary chromosomal abnormalities) with clinical and laboratory parameters
Time frame: Up to 10 years
Correlate specific karyotype groups with response rates, response duration, survival and cure in patients treated with various induction and post-induction regimens
Time frame: Up to 10 years
Correlate specific karyotype groups with selected molecular abnormalities as studied in CALGB leukemia protocols
Time frame: Up to 10 years
To correlate specific karyotype groups with multidrug resistance data
Time frame: Up to 10 years
To correlate specific karyotype groups with epidemiologic data (toxic exposure and family history)
Time frame: Up to 10 years
To determine karyotype changes at relapse and the influence of the type of change (or no change) in karyotype at relapse on subsequent clinical course
Time frame: up to 10 yeras
To identify new chromosome abnormalities important in leukemogenesis
Time frame: Up to 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Tunnell Cancer Center at Beebe Medical Center
Lewes, Delaware, United States
CCOP - Christiana Care Health Services
Newark, Delaware, United States
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Washington Cancer Institute at Washington Hospital Center
Washington D.C., District of Columbia, United States
Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
Fort Lauderdale, Florida, United States
...and 127 more locations